

HETEROCYCLES, Vol. 99, No. 2, 2019, pp. 1226 - 1238. © 2019 The Japan Institute of Heterocyclic Chemistry
Received, 23rd October, 2018, Accepted, 21st November, 2018, Published online, 15th February, 2019
DOI: 10.3987/COM-18-S(F)97

OPTIMIZED SYNTHESIS AND SOLID STATE INVESTIGATIONS ON THE DRUG CANDIDATE ENCENICLINE HYDROCHLORIDE

Gerhard Laus,^{1†} Sandro Neuner,^{1,2} Ramona Metz,¹ Thomas Müller,¹ Volker Kahlenberg,³ Thomas Gelbrich,¹ Sven Nerdinger,^{4*} Erwin Schreiner,⁴ Verena Adamer,⁴ Klaus Wurst,¹ and Herwig Schottenberger¹

¹University of Innsbruck, Faculty of Chemistry and Pharmacy, Innrain 80-82, 6020 Innsbruck, Austria. ²University for Health Sciences, Medical Informatics and Technology, Eduard-Wallnöfer-Zentrum 1, 6060 Hall in Tirol, Austria.

³Institute of Mineralogy and Petrography, Innrain 52, 6020 Innsbruck, Austria.

⁴Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria. E-mail: sven.nerdinger@sandoz.com

[†]Deceased December 22nd 2017.


This paper is dedicated to Professor Tohru Fukuyama on the occasion of his 70th birthday.

Abstract – For the production of drug substances a robust, scalable process delivering the active pharmaceutical ingredient (API) in excellent chemical and polymorphic purity is required. For this purpose we developed a novel imidazole-mediated one-pot procedure for the preparation of encenicline hydrochloride monohydrate, which crystallizes directly from the reaction mixture as pure non-hygroscopic polymorph (Form I). Solid state studies revealed a series of additional new physical forms for which crystal structures have been determined by single crystal X-ray diffraction.

INTRODUCTION

EVP-5141, better known as encenicline (**1**), is a potent selective partial agonist at the human $\alpha 7$ receptor exhibiting co-agonistic activity by enhancing the response to the natural agonist acetylcholine (ACh) as well as its release in the cortex, hippocampus, and nucleus accumbens.^{1,2} Furthermore, the researchers demonstrated good brain penetration after oral administration and a memory enhancing effect in rats in

vivo.¹ These findings and evidence from literature³⁻⁵ resulted in clinical studies evaluating **1** as cognition enhancer in schizophrenia as well as Alzheimer's disease patients.⁶



Patent literature discloses a two-step process for the preparation of **1** involving preparation of 7-chlorobenzo[*b*]thiophene-2-carboxylic acid **2** from 2,3-dichlorobenzaldehyde⁷ followed by amide bond formation with (*R*)-quinuclidin-3-amine dihydrochloride in the presence of Hünig's base (DIEA) and HATU as coupling agent.⁸ Purification by HPLC of the obtained residue and salt formation from dioxane/MeOH with hydrochloric acid provided **1** as hydrochloride in 65% yield. Other coupling agents used in the abovementioned patent disclosure are the systems HBTU/HOBt and EDC/HOBt. However, all these agents are rather expensive and require separation from the product in the course of an aqueous workup and/or chromatographic purification. Furthermore, it should be emphasized that bicyclooctanes bearing a nitrogen atom in the bridgehead-position, such as quinuclidine, and the related dibasic 1,4-diazabicyclo[2.2.2]octane (DABCO) are widely recognized for their preeminent basicity and nucleophilicity, which even allows access to chloromethyl-quarternized salts just by using dichloromethane as simple reactant.^{9,10} The rigid and compact cage-like molecular architecture of such structures constitutes an unusually favorable characteristic, for it effectively relieves the steric hindrance substitution or coordination, which in tertiary aliphatic amines arises from the flexibility of the nitrogen-bonded alkyl groups.¹¹ For example, the quinuclidine ring of potent 5-HT₃ receptor antagonists such as zacopride react with dichloromethane at room temperature to produce the corresponding chloromethyl quarternary derivatives.¹² Few others have also explored the formation of this type of originating from the abovementioned extraordinary reactivity features of the quinuclidinic nitrogen of cinchona alkaloids.^{13,14} Notably, these peculiarities came full circle, when the serendipitous discovery of N-fluoroquinuclidinium fluoride by Du-Boisson and Morton led to development of the bench stable, user-friendly 'F⁺'-transfer agent SelectfluorTM, based on cheap N-chloromethylated DABCONium chloride.¹⁵

RESULTS AND DISCUSSION

Keeping in mind the pre-published knowledge mentioned above, we also were curious regarding the feasibility of simultaneous acylation and chloromethylation. Hence, we also explored a standard coupling protocol for the Schotten-Baumann reaction in the presence of dichloromethane as solvent. For this, by treatment of **2** with thionyl chloride in toluene, we prepared the acid chloride **3** which was then reacted with (*R*)-quinuclidin-3-amine dihydrochloride in dichloromethane, additionally using triethylamine (TEA) as an auxiliary base (**A**). Not unexpected, after work-up and purification we did not isolate our amine target product **1**, but alkyl halide **4**, derived from the anticipated additional quaternization reaction of **1** with dichloromethane. The structure of **4** could be unambiguously confirmed via standard analytical techniques, as well as by single crystal X-ray structure determination as shown in Figure 1.





Figure 1. Molecular structure of **4** with non-H atoms represented as thermal ellipsoids drawn at the 50% probability level and H atoms drawn as spheres of arbitrary size


For the intentional preparation of **1** a switch to pyridine as solvent and base followed by subsequent stirring with a mixture of water/acetone at pH 8 gave the desired product, however, in only 35% yield (**B**). Further treatment of the free base with hydrochloric acid in diethyl ether gave the desired hydrochloride salt **1-HCl** in 68% yield for the salt formation step and 24% yield over all steps. Finally, we succeeded by using four equivalents imidazole in acetonitrile, which transforms **3** into the corresponding acylimidazole intermediate and concomitantly binds the hydrochloric acid formed (**C**). All three pathways A - C are shown in Scheme 1. Addition of one equivalent of water after completion of the reaction mediates crystallization of encenicline hydrochloride monohydrate Form I Y (**1-HCl**) from the reaction mixture in excellent chemical and polymorphic purity. Yields ranging between 75 and 78% were constantly reached, being above that reported in the literature (65%).⁸



Scheme 1. Preparation of encenicline **1** as the hydrochloride salt **1-HCl**

Stoner et al. have reported an imidazole-mediated peptide bond formation starting from an acyl chloride for the HIV protease inhibitor lopinavir.¹⁶ However, in their case the crude product obtained by evaporation of the solvent was just used for the next step.

In order to get a glimpse of the scope of this methodology, we used the same protocol for the reaction of benzoyl chloride (**5**) with (*R*)-quinuclidin-3-amine dihydrochloride and 1-methylpiperidin-4-amine dihydrochloride as shown in Scheme 2. Both transformations smoothly provided the desired products **6** and **7**, however, isolated yields (27 and 28%) of the crystalline materials were clearly lower, probably due to better solubility in acetonitrile, and thus would require further optimization work.



Scheme 2. Examples using that one-pot procedure in the preparation of the amides **6** and **7**

The crystals of form **A**, **Enc-HCl** · *i*-PrOH, **Enc-HCl** · *i*-BuOH, **Enc-HCl** · ace, **Enc-HCl** · DCM have the space group symmetry $P2_12_12_1$. The asymmetric unit contains one formula unit consisting of an

encenicline cation (Figure 2), a chloride anion and, in the case of a solvate, additionally one solvent molecule. A comparison of molecular packing arrangements with the program *XPac*¹⁷ confirmed that **Enc-HCl** · *i*-PrOH is isostructural with **Enc-HCl** · *i*-BuOH and that **Enc-HCl** · ace is isostructural with **Enc-HCl** · DCM (see Figure S1 of the Supporting Information).

The conformation of the encenicline cation can be characterized in terms of three torsion angles (see Figure 2). The cations of the four Enc-HCl solvates display nearly coplanar benzothiophene and acetamide fragments, resulting in a torsion angle S–C–N (τ_1 in Figure 1) close to 180°. By contrast, the planes defined by these two fragments form an angle of 24.1° in the cation of form **A**, and similar values are also found in the recently reported Enc-HCl monohydrates **I** – **III** (see Figure 3).¹⁸

The encenicline cation contains two NH groups (with atoms N13 and N16) which can serve as H-bond donor groups. In the isostructural **Enc-HCl** · ace and **Enc-HCl** · DCM solvates as well as in Form **A**, the chloride anion is used to form an N16–H16···Cl[−]···H13–N13 bridge between two cation moieties that are related by a 2₁ symmetry operation along the respective *a* axis (Figure 4a, b). In each case, the H16···Cl[−] bond [**A**: 2.15(3) Å] is significantly shorter than the H13···Cl[−] interaction [**A**: 2.46(3) Å]. The same type of N16–H16···Cl[−]···H13–N13 bridge is also present in the desolvates **I_D** – **III_D** of encenicline monohydrates reported by Bobrovs et al.,¹⁸ but the H16···Cl[−] (**IID**: 2.09 Å) and H13···Cl[−] (**IID**: 2.89 Å) distances differ even more substantially in these structures (see Table S1 of the Supporting Information). An analogous N16–H16···Cl[−]···H13–N13 bridge in the isostructural *i*-PrOH and *i*-BuOH solvates displays H16···Cl[−] and H13···Cl[−] bonds of approximately equal length [**Enc-HCl** · *i*-PrOH: 2.56(4) vs. 2.46(3) Å] and connects encenicline cations related by a translation along [100]. The relative elongation of H16···Cl[−] in comparison to the other Enc-HCl structures coincides with the involvement of the corresponding NH group in a second H-bond interaction with the carbonyl group of another cation, *i.e.* N16–H16···O11 [**Enc-HCl** · *i*-PrOH: H16···O11 = 2.23(4) Å]. As a result, the encenicline cations and Cl[−] anions of **Enc-HCl** · *i*-PrOH and **Enc-HCl** · *i*-BuOH are linked into an H-bonded layer structure parallel to the *ab* plane. An additional O–H···Cl[−] interaction [**Enc-HCl** · *i*-PrOH: H···Cl[−] = 2.27(3) Å] connects the respective solvent molecule with the chloride anion (Figure 4c).




Figure 2. Molecular structure of the encenicline cation and definition of the torsion angles τ_1 , τ_2 and τ_3 ¹⁸




Figure 3. Molecular conformation of the encenicline cation in various forms of Enc-HCl: form **A**, two pairs of isostructural solvates and three monohydrates **I – III**. The 7-chloro-1-benzothiophene fragment in the cation of **A** was used a template onto which the corresponding inflexible molecule fragment (drawn in balls and sticks style) of each other structures was least-squares fitted.




Figure 4. H-Bonded structures based on $N16-H16 \cdots Cl^- \cdots H13-N13$ interactions in solid forms of Enc-HCl: H-bonded chains in a) form **A**, b) **Enc-HCl · ace** and c) an H-bonded chain in **Enc-HCl · i-PrOH** with $O-H \cdots Cl^-$ bonded solvent molecule; additional $N16-H16 \cdots O11$ interactions between adjacent chains result in a H-bonded layer structure (not shown).

Table 1. Crystal data and structure refinement parameters for Enc-HCl form **A**, Enc-HCl solvates and **4**

	A	Enc-HCl · <i>i</i> -PrOH	Enc-HCl · <i>i</i> -BuOH	Enc-HCl · ace	Enc-HCl · DCM	4
Moiety formula	(C ₁₆ H ₁₈ ClN ₂ OS) ⁺ Cl ⁻	(C ₁₆ H ₁₈ ClN ₂ OS) ⁺ Cl ⁻ · C ₃ H ₈ O	(C ₁₆ H ₁₈ ClN ₂ OS) ⁺ Cl ⁻ · C ₄ H ₁₀ O	(C ₁₆ H ₁₈ ClN ₂ OS) ⁺ Cl ⁻ · C ₃ H ₈ O	(C ₁₆ H ₁₈ ClN ₂ OS) ⁺ Cl ⁻ · CH ₂ Cl ₂	(C ₁₇ H ₁₉ Cl ₂ N ₂ OS) ⁺ Cl ⁻
Empirical formula	C ₁₆ H ₁₈ Cl ₂ N ₂ O ₂ S	C ₁₉ H ₂₆ Cl ₂ N ₂ O ₂ S	C ₂₀ H ₂₈ Cl ₂ N ₂ O ₂ S	C ₁₉ H ₂₄ Cl ₂ N ₂ O ₂ S	C ₁₇ H ₂₀ Cl ₄ N ₂ O ₂ S	C ₁₇ H ₁₉ Cl ₃ N ₂ O ₂ S
Crystal system	Orthorhombic	Orthorhombic	Orthorhombic	Orthorhombic	Orthorhombic	Monoclinic
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁
<i>Z</i> / <i>Z'</i>	4 / 1	4 / 1	4 / 1	4 / 1	4 / 1	2 / 1
<i>a</i> , Å	7.4560(4)	6.6648(2)	6.69105(5)	6.95398(16)	6.99157(8)	6.2662(4)
<i>b</i> , Å	13.1119(5)	11.9701(3)	12.11066(9)	13.0688(3)	12.51368(13)	12.1960(9)
<i>c</i> , Å	18.4126(11)	26.2023(9)	26.2108(2)	22.2029(5)	22.5357(3)	12.1489(8)
β, °						101.667(3)
<i>V</i> , Å ³	1800.06(16)	2090.38(11)	2123.94(3)	2017.80(8)	1971.65(4)	909.27(11)
ρ _{calc.} , g · cm ⁻³	1.318	1.326	1.349	1.367	1.490	1.482
Goodness-of-fit on <i>F</i> ²	1.061	1.065	1.034	1.040	1.027	1.011
<i>R</i> 1 [<i>I</i> > 2σ(<i>I</i>)]	0.0514	0.0440	0.0523	0.0511	0.0433	0.0340
<i>wR</i> 2 (all data)	0.1415	0.1104	0.1395	0.1334	0.1142	0.0775
Flack parameter	0.0013(4)	-0.03(3)	0.001(8)	-0.003(15)	-0.022(10)	-0.04(3)
CCDC no.	1584187	1584188	1584190	1584186	1584189	1873281

EXPERIMENTAL

Reagents and solvents were purchased from Sigma-Aldrich. NMR spectra were recorded with a Bruker Avance DPX 300 spectrometer. IR spectra were obtained with a Bruker ALPHA Platinum FT-ATR instrument. High resolution mass spectra were measured with a Finnigan MAT 95 mass spectrometer. Elemental analyses have been conducted at the Laboratory for Microanalysis Services, Technical University of Vienna, Währingerstr. 42, 1090 Vienna, Austria (<https://chemie.univie.ac.at/en/services/service-facilities/lab-for-microanalysis-services>).

Single crystal X-ray determination

Intensity data for **A** and the Enc-HCl solvates were collected at 173 K on an Oxford Diffraction Gemini-R Ultra diffractometer operated by the CrysAlisPro¹⁹ software, using Cu radiation ($\lambda = 1.54184$ Å) or, in the case of Enc-HCl · *i*-PrOH, Mo radiation ($\lambda = 0.71073$ Å). Intensity data for **4** were collected at 213 K on a Bruker APEX-II CCD diffractometer (Mo radiation). The data were corrected for absorption effects, and the structures were solved with direct methods procedures implemented in SIR2002²⁰ or SHELXT,²¹

and full-matrix least-squares refinements on F^2 using SHELXL-2014 were carried out.²² Non-hydrogen atoms were located in difference maps and refined anisotropically. The hydrogen atoms bonded to C atoms were fixed in idealized positions and their thermal displacement parameters were set to $1.2U_{eq}$ (or $1.5U_{eq}$ or in the case of Me groups) of the parent C atom. All H atoms bonded to N or O atoms were located in difference maps and refined using distance restraints, whilst their thermal displacement parameters were refined freely. The absolute structures were determined on the basis of anomalous-dispersion effects in diffraction measurements on the crystal.

(R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate (1) (from 7-chlorobenzo[b]thiophene-2-carboxylic acid chloride)

To a stirred solution of 7-chlorobenzo[b]thiophene-2-carboxylic acid chloride (5.40 g, 23.4 mmol) in MeCN (100 mL) imidazole (3.18 g, 46.7 mmol) was added. Formation of a sticky precipitate was observed. Then, (*R*)-quinuclidin-3-amine dihydrochloride (4.75 g, 23.8 mmol) and imidazole (3.25 g, 47.7 mmol) in MeCN (50.0 mL) were added. The reaction mixture was then stirred at room temperature for 24 h. Next, water (0.42 g, 23.3 mmol) was added dropwise. Stirring was continued for 1 h. A crystalline product formed, was separated by filtration and then washed with MeCN (10 mL). Drying of the residue obtained in vacuo provided 6.84 g (78%) of crystalline encenicline hydrochloride monohydrate Form I. The identity of the product with (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate was confirmed by ¹H NMR in DMSO-*d*₆. The NMR data were in agreement with known literature or patent data.⁸ ¹H-NMR (300 MHz, DMSO-*d*₆): δ 1.75 (m, 1 H), 1.92 (m, 2 H), 2.02-2.28 (m, 2 H), 3.10-3.77 (m, 6 H), 4.33 (m, 1 H), 7.52 (dd, 1 H), 7.63 (m, 1 H), 7.98 (m, 1 H), 8.43 (s, 1 H), 9.17 (d, 1 H), 10.03 (s, 1 H, br) ppm. ¹³C NMR (75 MHz, DMSO-*d*₆): δ 19.9, 25.7, 25.9, 46.4, 46.9, 47.6, 53.5, 124.4, 125.6, 126.6, 138.9, 140.7, 141.1, 161.6 ppm. HRMS (ESI⁺): M+H⁺ for C₁₆H₁₇ClN₂OS calcd. 321.0823; found 321.0817. Anal. Calcd for C₁₆H₂₀Cl₂N₂O₂S: C, 51.21; H, 5.37; N, 7.46; S, 8.55. Found: C, 50.57; H, 5.29; N, 7.38; S, 8.36.

(R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate (1) (from 7-chlorobenzo[b]thiophene-2-carboxylic acid - one-pot procedure)

To 7-chlorobenzo[b]thiophene-2-carboxylic acid (5.00 g, 23.5 mmol) in toluene (3.00 mL) thionyl chloride (15.0 mL, 207 mmol) was added and the mixture stirred at 85 °C for 4 h. The clear solution was cooled down to room temperature and toluene together with volatile remains of the reagent was removed in vacuo. To the residue were added 5 mL of toluene and the solvent was again removed in vacuo. Then MeCN (100 mL) and imidazole (3.18 g, 46.7 mmol) were added to the crude

7-chlorobenzo[*b*]thiophene-2-carboxylic acid chloride (5.40 g, 23.4 mmol). Formation of a sticky precipitate was observed. Then, (*R*)-quinuclidin-3-amine dihydrochloride (4.75 g, 23.8 mmol), imidazole (3.25 g, 47.7 mmol) in MeCN (50 mL) were added. The reaction mixture was then stirred at room temperature for 24 h. Next, water (0.42 g, 23.3 mmol) was added dropwise. Stirring was continued for 1 h. The crystalline product was separated by filtration and washed with MeCN (10 mL). Drying of the obtained residue in vacuo provided crystalline encenicline hydrochloride monohydrate Form I.

(*R*)-7-Chloro-N-1-chloromethyl-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide chloride (4)

A solution of 7-chlorobenzo[*b*]thiophene-2-carboxylic acid chloride (1.00 g, 4.3 mmol) in CH₂Cl₂ (10.0 mL) was added in a dropwise manner to a solution of (*R*)-quinuclidin-3-amine dihydrochloride (0.86 g, 4.30 mmol) in triethylamine (1.80 mL, 13.0 mmol). The mixture was stirred at 22 °C for 48 h and a brown precipitate formed. The crude product was removed by filtration, washed with CH₂Cl₂ (2 x 2 mL) and dried in high vacuum (2.10 g). This material was stirred with saturated aqueous sodium bicarbonate solution (10.0 mL) and then 1N aqueous sodium hydroxide (12 mL). A clear solution resulted upon the addition of water (20.0 mL). CH₂Cl₂ (30.0 mL) was added and the pH was adjusted to 7 with diluted hydrochloric acid and sodium hydrogencarbonate and then the mixture was stirred for 30 min. An insoluble precipitate formed and was removed by filtration. It was washed sparingly with water and dried to obtain 0.21 g of compound (**4**) in 12% yield. ¹H-NMR (300 MHz, DMSO-*d*₆): δ 1.92 (m, 1 H), 2.06 (m, 2 H), 2.27 – 3.32 (m, 2 H), 3.50 – 3.72 (m, 5 H), 3.96 (t, 1 H), 4.42 (bd, 1 H), 5.31 (s, 2 H, N-CH₂-Cl), 7.52 (t, *J* = 7.8 Hz, 1 H), 7.63 (d, *J* = 7.6 Hz, 1 H), 7.97 (d, *J* = 7.9 Hz, 1 H), 8.44 – 8.46 (m, 1 H), 9.31 (m, 1 H) ppm. ¹³C NMR (75 MHz, DMSO-*d*₆): δ 18.18, 21.86, 24.47, 45.60, 52.79, 52.88, 57.45, 67.79, 124.37, 125.96, 126.54, 126.80, 126.97, 139.00, 139.97, 140.51, 161.64 ppm. IR (neat): ν 3236 (w), 2997 (w), 2977 (w), 1641 (s), 1534 (s), 1455 (m), 1320 (m), 1282 (m), 1216 (m), 1091 (m), 898 (m), 789 (s), 711 (s), 602 (m) cm⁻¹. HRMS (ESI⁺): M+H⁺ for C₁₇H₁₉Cl₂N₂OS calcd. 369.0595; found 369.0590.

Single crystals of (*R*)-7-chloro-N-1-chloromethyl-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide chloride (4)

(*R*)-7-Chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride (500 mg) was dissolved in a mixture of CH₂Cl₂ (10 mL) and 1M aqueous sodium hydroxide (10.0 mL). The organic layer was removed and the aqueous layer extracted with CH₂Cl₂ twice (5.00 mL each). The combined organic extracts were dried over anhydrous sodium sulfate. Aliquots of the resulting CH₂Cl₂ solution of the free base were stored in glass vials at room temperature for three days while crystals grew. The crystalline material was analyzed via NMR spectroscopy and found to give identical spectra as compound

(4), as prepared from the acid chloride (3) and (*R*)-quinuclidin-3-amine dihydrochloride. The resulting crystals were screened for a suitable single crystal for data collection.

Single crystals of (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride form A

(*R*)-7-Chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride monohydrate form I was annealed on a Kofler hot bench at 250 °C for 3 h in a sublimation ring whereat single crystals of anhydrous (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride form A were formed.

Single crystals of (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride isopropanol solvate

(*R*)-7-Chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride monohydrate form I (100 mg) was suspended in *i*PrOH (0.50 mL) and heated to reflux temperature. After separation of the solution from the remaining solid by filtration the hot solution was allowed to cool to room temperature whereat single crystals appear within 24 h.

Single crystals of (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride isobutanol solvate

(*R*)-7-Chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride monohydrate form I (50.0 mg) was dissolved in *i*BuOH (5.00 mL) and heated to a jacket temperature of 120 °C. The water in the crystal lattice was removed by azeotrope distillation. After 3 h the solution was allowed to cool and single crystals could be isolated at room temperature.

Single crystals of (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride acetone solvate

(*R*)-7-Chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride monohydrate form I (50.0 mg) was suspended in acetone (2.00 mL) and heated to reflux temperature. The resulting hot clear solution was filtrated and the solvent was allowed to evaporate through a cannula.

Single crystals of (*R*)-7-chloro-N-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride dichloromethane solvate

(*R*)-7-Chloro-*N*-(quinuclidin-3-yl)benzo[*b*]thiophene-2-carboxamide hydrochloride monohydrate form I (50.0 mg) was suspended in CH₂Cl₂ (2.00 mL) and heated to reflux temperature. The resulting hot clear solution was filtrated and the solvent was allowed to evaporate through a cannula.

(*R*)-*N*-(Quinuclidin-3-yl)benzamide hydrochloride (6) (from benzenecarboxylic acid chloride - one-pot)

To a solution of imidazole (0.68 g, 10.0 mmol) in MeCN (10.0 mL) benzoyl chloride (0.67 g, 4.80 mmol) in MeCN (1 mL) was slowly added at room temperature. Formation of a sticky precipitate was observed. Then, solid (*R*)-quinuclidin-3-amine dihydrochloride (1.00 g, 5.00 mmol) and solid imidazole (0.68 g, 10.0 mmol) were added. The reaction mixture was then stirred at room temperature until completion. Then, water (0.09 g, 5.00 mmol) was added dropwise. Stirring was continued for 3 h. The crystalline product was separated by filtration and washed with Et₂O (5.00 mL). Drying of the residue obtained in vacuo provided 370 mg (27%) pure (*R*)-*N*-(quinuclidin-3-yl)benzamide hydrochloride as a crystalline solid. Mp 248 °C (upon a phase transition at 217- 220 °C), Mp 245 °C.²³ ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.69 (m, 1 H), 1.89 (m, 2 H), 2.10 (m, 1 H), 2.17 (m, 1 H), 3.17 (m, 3 H), 3.38 (m, 2 H), 3.58 (m, 1 H), 4.33 (m, 1 H), 7.46 (t, *J* = 7.3 Hz, 2 H), 7.54 (t, *J* = 7.2 Hz, 1 H), 7.96 (d, *J* = 7.0 Hz, 2 H), 8.84 (d, *J* = 6.1 Hz, 1 H), 10.8 (br, 1 H) ppm. ¹³C NMR (75 MHz, DMSO-*d*₆): δ 17.2, 21.5, 24.5, 44.7, 44.9, 45.3, 50.2, 127.6 (2C), 128.2 (2C), 131.4, 133.9, 166.7 ppm. IR (neat): ν 3230 (w), 2916 (w), 2632 (w), 2538 (m), 2479 (m), 1651 (s), 1521 (s), 1486 (m), 1311 (m), 707 (s), 619 (s) cm⁻¹. HRMS (ESI⁺): M+H⁺ for C₁₄H₁₈N₂O calcd. 231.1492; found 231.1488. Anal. Calcd for C₁₄H₂₁ClN₂O₂: C, 59.05; H, 7.43; N, 9.84. Found: C, 59.13; H, 7.04; N, 10.12.

***N*-(1-Methyl-4-piperidiny)benzamide hydrochloride (7)** (from benzenecarboxylic acid chloride - one-pot)

To a solution of imidazole (0.36 g, 5.30 mmol) in MeCN (5.00 mL) benzoyl chloride (0.36 g, 2.50 mmol) in MeCN (1.00 mL) was slowly added at room temperature. Formation of a sticky precipitate was observed. Then, solid 4-amino-1-methylpiperidine dihydrochloride (0.50 g, 2.70 mmol) and solid imidazole (0.36 g, 5.30 mmol) were added. The reaction mixture was then stirred at room temperature until completion. Then, water (0.05 g, 5.00 mmol) was added dropwise. Stirring was continued for 3 h. The crystalline product was separated by filtration and washed with Et₂O (5.00 mL). Drying of the residue obtained in vacuo provided 190 mg (28%) *N*-(1-methyl-4-piperidiny)benzamide hydrochloride as a crystalline solid. Mp 213-214 °C (upon a phase transition at 205 °C), Mp 207-209 °C.²⁴ ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.97 (m, 4 H), 2.69 (s, 3 H), 3.37 (m, 4 H), 4.02 (m, 1 H), 7.44 (t, *J* = 7.2 Hz, 2 H), 7.52 (t, *J* = 7.2 Hz, 1 H), 7.89 (d, *J* = 7.2 Hz, 1 H), 8.60 (d, *J* = 6.4 Hz, 1 H), 11.0 (br, 1 H) ppm. ¹³C

NMR (75 MHz, DMSO-*d*₆): δ 28.6, 42.4, 44.4, 52.4, 127.4, 128.1, 131.2, 134.2, 165.8 ppm. IR (neat): ν 3243 (w), 3055 (w), 2945 (w), 2455 (m), 1628 (s), 1537 (s), 1467 (m), 1311 (m), 960 (m), 696 (s) cm⁻¹. HRMS (ESI⁺): M+H⁺ for C₁₃H₁₈N₂O calcd. 219.1492; found 219.1488.

ACKNOWLEDGEMENTS

We are grateful to Prof. Dr. Gunther Heymann for his support on crystallographic data collection and Mag. Johannes Theiner for elemental analyses upon short notice.

REFERENCES

1. J. Prickaerts, N. P. van Goethem, R. Chesworth, G. Shapiro, F. G. Boess, C. Methfessel, O. A. H. Reneerkens, D. G. Flood, D. Hilt, M. Gawryl, S. Bertrand, D. Bertrand, and G. König, *Neuropharmacology*, 2012, **62**, 1099.
2. M. Huang, A. R. Felix, D. G. Flood, C. Bhuvaneshwaran, D. Hilt, G. Koenig, and H. Y. Meltzer, *Psychopharmacology*, 2014, **231**, 4541.
3. W. R. Kem, *Behav. Brain Res.*, 2000, **113**, 169.
4. St. C. Leiser, M. R. Bowlby, T. A. Comery, and J. Dunlop, *Pharmacol. Ther.*, 2009, **122**, 302.
5. M. S. Thomsen, H. H. Hansen, M. B. Timmerman, and J. D. Mikkelsen, *Curr. Pharm. Des.*, 2010, **16**, 323.
6. J. H. Magnussen, A. Ettrup, C. K. Donat, D. Peters, M. H. F. Pedersen, G. M. Knudsen, and J. D. Mikkelsen, *Eur. J. Pharmacol.*, 2015, **762**, 35.
7. W. G. Brower, *Int. Pat.*, WO1999/047510.
8. M. Hendrix, F.-G. Böß, C. Erb, T. Fleßner, M. Van Kampen, J. Luthle, C. Methfessel, and W. B. Wiese, *Int. Pat.*, WO2003/055878.
9. L. M. Vallarino, V. L. Goedken, and J. V. Quagliano, *Inorg. Chim. Acta*, 1978, **29**, 125.
10. L. M. Vallarino, V. L. Goedken, and J. V. Quagliano, *Inorg. Chem.*, 1973, **12**, 102.
11. J. V. Quagliano, A. K. Banerjee, V. L. Goedken, and L. M. Vallarino, *J. Am. Chem. Soc.*, 1970, **92**, 482.
12. M. Langlois, J. L. Soulier, M. Mathe-Allainmat, C. Gallais, B. Bremont, and S. Shen, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 945.
13. R. Schumacher, M. D. Danca, J. Ma, B. Herbert, T. M. Nguyen, W. Xie, Wenge, and A. Tehim, *Int. Pat.*, WO 2007/038367.
14. C. M. Bourdin, J. Lebreton, M. Mathé-Allainmat, and St. H. Thany, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3184.
15. R. Eric Banks, M. K. Besheesh, S. N. Mohialdin-Khaffaf, and I. Sharif, *J. Chem. Soc., Perkin Trans.*

- I*, 1996, 2069.
16. E. J. Stoner, P. J. Stengel, and A. J. Cooper, *Org. Process Res. Dev.*, 1999, **3**, 145.
 17. T. Gelbrich and M. B. Hursthouse, *CrystEngComm*, 2005, **7**, 324.
 18. R. Bobrovs, A. Kons, A. Bērziņš, T. Rekis, and A. Actiņš, *Cryst. Growth Des.*, 2018, **18**, 2100.
 19. *CrysAlis PRO*, 2015, Rigaku Corporation, Tokyo, Japan.
 20. M. C. Burla, M. Camalli, B. Carrozzini, G. L. Casciarano, C. Giacovazzo, G. Polidori, and R. Spagna, *J. Appl. Cryst.*, 2003, **36**, 1103.
 21. G. Sheldrick, *Acta Crystallogr., Sect. A: Fundam. Crystallogr.*, 2015, **71**, 3.
 22. G. Sheldrick, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, 2015, **71**, 3.
 23. A. Renaud, M. Langlois, R. J. Naylor, and B. Naylor, *Europ. Pat.*, EP0311724
 24. *Sandoz Ltd., GB. Pat.*, 1955, 740307.